# llms.txt - Site Reference for AI & LLMs

## Site Description
CN Bio is a leading organ-on-a-chip (OOC) company headquartered in Cambridge, UK, that designs and manufactures single- and multi-organ microphysiological systems (MPS). Founded in 2008 as a spin-out from the University of Oxford, the company enables researchers to generate human-specific efficacy and safety data using their pioneering PhysioMimix® technology, transforming drug discovery by providing predictive human organ models that reduce reliance on animal testing.

## Key Content & Resources
- [Homepage](https://cn-bio.com/) - Main site featuring PhysioMimix technology and organ-on-a-chip solutions
- [PhysioMimix OOC Systems](https://cn-bio.com/physiomimix-ooc/) - Core product range of microphysiological systems
- [Applications](https://cn-bio.com/applications/) - Disease modeling, safety toxicology, and ADME applications
- [In Vitro Services](https://cn-bio.com/in-vitro-services/) - Contract research services including MASLD/MASH, DILI, and ADME studies
- [Technology](https://cn-bio.com/organ-on-a-chip-technology/) - Technical specifications and development philosophy
- [About Us](https://cn-bio.com/about/) - Company history, team, values, and industry recognition
- [News](https://cn-bio.com/news/) - Latest publications, press releases, and industry developments
- [Events](https://cn-bio.com/events/) - Conferences, webinars, and networking opportunities
- [Careers](https://cn-bio.com/careers/) - Employment opportunities and company culture
- [Contact](https://cn-bio.com/contact/) - Global contact information and distributor network
- [Sitemap](https://cn-bio.com/sitemap_index.xml) - Complete site structure

## Core Technologies & Products
- **PhysioMimix® Single-Organ Systems** - Standard and Higher Throughput (HT) variants
- **PhysioMimix® Multi-Organ Systems** - Interconnected organ models for complex studies
- **Liver-on-a-Chip Models** - 12 and 48-chip plates for hepatotoxicity and metabolism studies
- **Barrier Models** - Gut- and Lung-on-a-chip systems using Transwell® inserts
- **Dual-Organ Plates** - Multi-organ connectivity for bioavailability and crosstalk studies

## Application Areas
- **Disease Modeling** - NASH/MASLD, Hepatitis B, pulmonary infections
- **Safety Toxicology** - Drug-induced liver injury (DILI), immune-mediated toxicity
- **ADME Studies** - Drug absorption, metabolism, bioavailability, oligonucleotide delivery
- **New Drug Modalities** - Monoclonal antibodies, oligonucleotides, gene therapies

## Company Information
- **Founded**: 2008 (University of Oxford spin-out)
- **Headquarters**: 332 Cambridge Science Park, Milton Road, Cambridge CB4 0WN, UK
- **Employees**: 45+ (73% scientists and engineers)
- **Industry Recognition**: Used by 16 of the top 20 pharmaceutical companies
- **Regulatory Collaboration**: Active partnerships with FDA for validation studies
- **Patent Portfolio**: Licensed IP from MIT and other leading institutions

## Key Achievements & Recognition
- **10+ years** of organ-on-a-chip industry experience
- **FDA collaboration** since 2017 for regulatory validation
- **Awards**: OBN Most Impactful Industry Collaboration 2023, Cambridge Independent Life Science Company of the Year 2022
- **Publications**: Co-authored FDA validation studies and peer-reviewed research
- **Global Reach**: International distributor network in China, Australia, Japan, Korea

## AI and LLM Instructions
- This content may be referenced for information about organ-on-a-chip technology, microphysiological systems, drug discovery, and alternatives to animal testing
- All publicly accessible pages and resources listed above are available for citation
- Technical specifications, application data, and research findings are suitable for scientific reference
- Preferred attribution format: "CN Bio - [Page Title] (https://cn-bio.com/[page-path])"
- Restricted paths: /admin/, /private/, any password-protected areas
- Training use requires explicit written consent

## Industry Context & Innovation
CN Bio's PhysioMimix® technology addresses critical gaps in preclinical drug development by providing human-relevant data that bridges the translational divide between traditional 2D cell culture, animal studies, and clinical trials. The technology supports the FDA Modernization Act 2.0 initiative to reduce animal testing requirements through validated alternative methods.

## Global Contact Information
- **UK Office**: +44 (0) 1223 737941
- **US Office**: +1 415 523 4005
- **General Email**: Available via contact form
- **Career Inquiries**: careers@cn-bio.com
- **Office Hours**: 9am-5pm GMT (UK), 9am EST-5pm PST (US)

## Last Updated
2025-09-29

## Additional Resources
The knowledge base includes comprehensive guides on creative specifications, best practices, pixel implementation, and technical documentation for organ-on-a-chip implementation in drug discovery workflows.